Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Boule Diagnostics

BATS-CHIXE:BOULS
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BOULS
BATS-CHIXE
SEK1B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
  • Boule Diagnostics has significant price volatility in the past 3 months.
BOULS Share Price and Events
7 Day Returns
22.4%
BATS-CHIXE:BOULS
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-3.5%
BATS-CHIXE:BOULS
-0.3%
GB Medical Equipment
-23.6%
GB Market
BOULS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Boule Diagnostics (BOULS) 22.4% -8% -12.1% -3.5% -4.1% -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • BOULS underperformed the Medical Equipment industry which returned -0.3% over the past year.
  • BOULS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
BOULS
Industry
5yr Volatility vs Market
Related Companies

BOULS Value

 Is Boule Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Boule Diagnostics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Boule Diagnostics.

BATS-CHIXE:BOULS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:BOULS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 22%) (13.96%))
0.93
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.93 * 5.44%)
5.59%

Discounted Cash Flow Calculation for BATS-CHIXE:BOULS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Boule Diagnostics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:BOULS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 5.59%)
2020 28.00 Analyst x1 26.52
2021 64.50 Analyst x2 57.85
2022 83.20 Analyst x2 70.67
2023 84.60 Analyst x1 68.06
2024 93.10 Analyst x1 70.93
2025 98.97 Est @ 6.31% 71.41
2026 103.50 Est @ 4.57% 70.73
2027 106.98 Est @ 3.36% 69.23
2028 109.66 Est @ 2.51% 67.22
2029 111.77 Est @ 1.92% 64.88
Present value of next 10 years cash flows SEK637.00
BATS-CHIXE:BOULS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK111.77 × (1 + 0.53%) ÷ (5.59% – 0.53%)
SEK2,220.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK2,220.72 ÷ (1 + 5.59%)10
SEK1,289.10
BATS-CHIXE:BOULS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK637.00 + SEK1,289.10
SEK1,926.10
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK1,926.10 / 19.42
SEK99.2
BATS-CHIXE:BOULS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:BOULS represents 0.96452x of OM:BOUL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96452x
Value per Share
(Listing Adjusted, SEK)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 99.20 x 0.96452
SEK95.68
Value per share (SEK) From above. SEK95.68
Current discount Discount to share price of SEK59.80
= -1 x (SEK59.80 - SEK95.68) / SEK95.68
37.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Boule Diagnostics is available for.
Intrinsic value
37%
Share price is SEK59.8 vs Future cash flow value of SEK95.68
Current Discount Checks
For Boule Diagnostics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Boule Diagnostics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Boule Diagnostics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Boule Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Boule Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:BOULS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK1.93
OM:BOUL Share Price ** OM (2020-04-07) in SEK SEK62
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Boule Diagnostics.

BATS-CHIXE:BOULS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:BOUL Share Price ÷ EPS (both in SEK)

= 62 ÷ 1.93

32.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Boule Diagnostics is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Boule Diagnostics is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Boule Diagnostics's expected growth come at a high price?
Raw Data
BATS-CHIXE:BOULS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 32.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
23%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:BOULS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 32.12x ÷ 23%

1.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Boule Diagnostics is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Boule Diagnostics's assets?
Raw Data
BATS-CHIXE:BOULS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK17.15
OM:BOUL Share Price * OM (2020-04-07) in SEK SEK62
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:BOULS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:BOUL Share Price ÷ Book Value per Share (both in SEK)

= 62 ÷ 17.15

3.62x

* Primary Listing of Boule Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Boule Diagnostics is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Boule Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Boule Diagnostics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BOULS Future Performance

 How is Boule Diagnostics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Boule Diagnostics expected to grow at an attractive rate?
  • Boule Diagnostics's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Boule Diagnostics's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Boule Diagnostics's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:BOULS Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:BOULS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 23%
BATS-CHIXE:BOULS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 6.3%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:BOULS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:BOULS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 589 104 74 2
2021-12-31 549 85 64 2
2020-12-31 485 65 46 2
2020-04-07
BATS-CHIXE:BOULS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 499 54 38
2019-09-30 476 41 32
2019-06-30 456 16 21
2019-03-31 444 11 36
2018-12-31 424 23 41
2018-09-30 425 40 48
2018-06-30 424 51 60
2018-03-31 421 46 43
2017-12-31 428 58 37
2017-09-30 422 45 31
2017-06-30 421 38 28
2017-03-31 419 32 38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Boule Diagnostics's earnings are expected to grow significantly at over 20% yearly.
  • Boule Diagnostics's revenue is expected to grow by 6.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:BOULS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Boule Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BOULS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 3.75 3.84 3.65 2.00
2021-12-31 3.25 3.41 3.09 2.00
2020-12-31 2.32 2.83 1.80 2.00
2020-04-07
BATS-CHIXE:BOULS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 1.93
2019-09-30 1.70
2019-06-30 1.09
2019-03-31 1.85
2018-12-31 2.11
2018-09-30 2.46
2018-06-30 3.06
2018-03-31 2.25
2017-12-31 1.94
2017-09-30 1.60
2017-06-30 1.51
2017-03-31 2.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Boule Diagnostics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Boule Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Boule Diagnostics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BOULS Past Performance

  How has Boule Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Boule Diagnostics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Boule Diagnostics's year on year earnings growth rate has been positive over the past 5 years.
  • Boule Diagnostics's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Boule Diagnostics's 1-year earnings growth is negative, it can't be compared to the GB Medical Equipment industry average.
Earnings and Revenue History
Boule Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Boule Diagnostics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:BOULS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 498.90 37.50 128.10 29.90
2019-09-30 475.80 31.83 126.24 30.72
2019-06-30 455.50 21.23 123.94 32.72
2019-03-31 443.50 35.93 115.14 32.52
2018-12-31 424.40 41.03 109.64 28.82
2018-09-30 425.49 47.64 111.44 23.50
2018-06-30 424.19 59.64 111.74 24.50
2018-03-31 420.69 43.44 110.74 26.90
2017-12-31 427.79 37.24 115.54 31.70
2017-09-30 422.31 30.63 113.56 37.78
2017-06-30 421.21 28.33 110.06 38.08
2017-03-31 418.91 38.43 108.86 38.48
2016-12-31 396.71 36.03 105.16 37.48
2016-09-30 383.31 35.85 96.57 39.57
2016-06-30 363.61 21.55 95.57 42.17
2016-03-31 340.51 15.05 93.07 42.07
2015-12-31 331.41 15.35 89.07 40.07
2015-09-30 333.09 28.87 95.06 30.83
2015-06-30 317.89 33.27 91.16 26.03
2015-03-31 308.69 32.57 88.66 23.43
2014-12-31 306.69 30.27 87.56 23.63
2014-09-30 288.80 13.58 82.75 24.24
2014-06-30 285.10 -68.33 82.65 25.24
2014-03-31 286.70 -64.13 83.75 24.34
2013-12-31 276.80 -70.13 84.15 24.14
2013-09-30 280.94 -64.93 85.20 24.64
2013-06-30 274.79 8.37 85.69 23.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Boule Diagnostics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Boule Diagnostics used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Boule Diagnostics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Boule Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Boule Diagnostics has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BOULS Health

 How is Boule Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Boule Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Boule Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Boule Diagnostics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Boule Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Boule Diagnostics Company Filings, last reported 3 months ago.

BATS-CHIXE:BOULS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 332.90 100.70 21.60
2019-09-30 333.40 92.00 19.20
2019-06-30 303.70 94.20 17.00
2019-03-31 314.30 87.00 16.80
2018-12-31 300.86 72.41 30.26
2018-09-30 298.70 41.60 39.10
2018-06-30 290.10 54.30 61.90
2018-03-31 278.20 55.20 104.70
2017-12-31 261.77 63.33 99.16
2017-09-30 247.10 62.60 74.60
2017-06-30 223.90 67.00 66.60
2017-03-31 236.60 61.20 65.90
2016-12-31 229.77 53.90 44.59
2016-09-30 223.20 56.00 37.00
2016-06-30 202.30 18.30 16.60
2016-03-31 192.60 20.50 19.10
2015-12-31 188.51 65.05 50.40
2015-09-30 187.60 45.70 19.10
2015-06-30 181.30 53.80 17.60
2015-03-31 185.90 50.70 19.50
2014-12-31 169.99 44.99 22.66
2014-09-30 148.50 57.70 24.80
2014-06-30 133.80 47.70 23.40
2014-03-31 131.50 41.40 11.60
2013-12-31 127.49 40.29 11.05
2013-09-30 128.50 43.89 20.29
2013-06-30 203.74 38.52 19.32
  • Boule Diagnostics's level of debt (30.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (26.4% vs 30.2% today).
  • Debt is well covered by operating cash flow (53.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 15.9x coverage).
X
Financial health checks
We assess Boule Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Boule Diagnostics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BOULS Dividends

 What is Boule Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.97%
Current annual income from Boule Diagnostics dividends. Estimated to be 1.53% next year.
If you bought SEK2,000 of Boule Diagnostics shares you are expected to receive SEK19 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Boule Diagnostics's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Boule Diagnostics's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:BOULS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:BOULS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 1.15 2.00
2021-12-31 0.98 2.00
2020-12-31 0.73 2.00
2020-04-07
BATS-CHIXE:BOULS Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2020-02-07 0.600 0.973
2019-04-15 0.550 1.020
2019-02-07 0.550 0.890
2018-04-23 0.500 0.702
2018-02-16 0.500 0.716
2017-04-20 0.350 0.503
2017-02-16 0.350 0.533
2016-04-21 0.150 0.459
2016-02-18 0.150 0.862
2015-04-21 0.150 0.713
2015-02-13 0.150 0.732
2014-04-22 0.125 0.965
2014-02-07 0.125 1.165
2013-04-02 0.125 1.243
2013-02-19 0.125 1.188

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Boule Diagnostics is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Boule Diagnostics is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Boule Diagnostics's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Boule Diagnostics's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.3x coverage).
X
Income/ dividend checks
We assess Boule Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Boule Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Boule Diagnostics has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BOULS Management

 What is the CEO of Boule Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christina Rubenhag
AGE 48
TENURE AS CEO 0.3 years
CEO Bio

Ms. Christina Rubenhag serves as Acting CEO and Group President at Boule Diagnostics AB (publ) since 2020. Ms. Rubenhag served the Chief Financial Officer and Senior Vice President of Boule Diagnostics AB (publ) since October 11, 2017 until 2020. Ms. Rubenhag served as the Chief Executive Officer of Sophion Holding AB since February 10, 2017 until July 6, 2017. She served as the Chief Executive Officer of Biolin Scientific Holding AB (formerly Biolin Scientific AB (publ)) from March 2016 to February 10, 2017 and also served as its Chief Financial Officer until February 10, 2017. She served as the Chief Financial Officer and Human Resource Executive at PacketFront Holding AB. Ms. Rubenhag has a Master of Business Administration from Umeå School of Business in Sweden. She holds Bachelor of Science from the Umeå School of Business and Economics.

CEO Compensation
  • Insufficient data for Christina to compare compensation growth.
  • Insufficient data for Christina to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Boule Diagnostics management team in years:

2.5
Average Tenure
56
Average Age
  • The tenure for the Boule Diagnostics management team is about average.
Management Team

Christina Rubenhag

TITLE
Acting CEO & Group President
AGE
48
TENURE
0.3 yrs

Eva Ekermann

TITLE
Human Resources Director
TENURE
2.3 yrs

Karen Bornstein

TITLE
Head of Marketing
TENURE
16.3 yrs

Mike Eliott

TITLE
Head of Development - Reagents & Consumables
TENURE
28.3 yrs

Christina Hugosson

TITLE
Head of Development - Instruments & Systems
AGE
56
TENURE
13.3 yrs

Debbie Herrera

TITLE
Senior Vice President of Quality & Regulatory
TENURE
3.3 yrs

Fredrik Ekdahl

TITLE
Senior Vice President of R&D
TENURE
2.8 yrs

Kiarash Farr

TITLE
Senior Vice President of Commercial Operations
TENURE
2.1 yrs

Bob Ariano

TITLE
Senior Vice President of Commercial Operations for US
TENURE
0.8 yrs

Mikael Ekholm

TITLE
Senior Vice President of Instrument Production
AGE
57
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Boule Diagnostics board of directors in years:

4.3
Average Tenure
58
Average Age
  • The tenure for the Boule Diagnostics board of directors is about average.
Board of Directors

Peter von Ehrenheim

TITLE
Chairman of the Board
COMPENSATION
SEK450K
AGE
64
TENURE
4.3 yrs

Thomas Eklund

TITLE
Independent Director
COMPENSATION
SEK225K
AGE
52
TENURE
6.3 yrs

Karin Dahllof

TITLE
Director
COMPENSATION
SEK225K
AGE
60
TENURE
5.3 yrs

Jon Risfelt

TITLE
Independent Director
COMPENSATION
SEK225K
AGE
58
TENURE
4.3 yrs

Charlotta Falvin

TITLE
Independent Director
COMPENSATION
SEK225K
AGE
53
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
28. Sep 19 Buy Christina Rubenhag Individual 26. Sep 19 26. Sep 19 800 SEK43.95 SEK35,160
21. Aug 19 Buy Christina Rubenhag Individual 15. Aug 19 15. Aug 19 2,500 SEK40.62 SEK101,550
20. Aug 19 Buy Thomas Eklund Individual 16. Aug 19 20. Aug 19 17,203 SEK38.76 SEK666,086
16. Aug 19 Buy Karin Dahllof Individual 15. Aug 19 15. Aug 19 2,900 SEK39.00 SEK113,100
25. Jun 19 Buy Karin Dahllof Individual 25. Jun 19 25. Jun 19 3,750 SEK53.36 SEK200,100
20. Jun 19 Buy Thomas Eklund Individual 20. Jun 19 20. Jun 19 150,000 SEK53.00 SEK7,950,000
X
Management checks
We assess Boule Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Boule Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BOULS News

Simply Wall St News

BOULS Company Info

Description

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary clinical chemistry analyzer and diagnostics systems under the Exigo brand. The company sells its products directly in Sweden and the United States, as well as through distributors internationally. It serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and companies in blood diagnostics. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Spånga, Sweden.

Details
Name: Boule Diagnostics AB (publ)
BOULS
Exchange: BATS-CHIXE
Founded: 1956
SEK1,098,976,843
19,416,552
Website: http://www.boule.com
Address: Boule Diagnostics AB (publ)
Domnarvsgatan 4,
Spånga,
Stockholm County, 163 53,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM BOUL Common Shares OMX Nordic Exchange Stockholm SE SEK 23. Jun 2011
OTCPK BDAB.F Common Shares Pink Sheets LLC US USD 23. Jun 2011
BST 8BD Common Shares Boerse-Stuttgart DE EUR 23. Jun 2011
LSE 0P4Z Common Shares London Stock Exchange GB SEK 23. Jun 2011
BATS-CHIXE BOULS Common Shares BATS 'Chi-X Europe' GB SEK 23. Jun 2011
Number of employees
Current staff
Staff numbers
0
Boule Diagnostics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 21:31
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/07
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.